Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | TYK2 | P29597 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598015 | 0.80 | SERPINE1 (0.47) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL4417699 | 0.77 | KDM4E (0.58) | — | |
| SCHEMBL6685720 | 0.72 | PARP1 (0.63) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL15995019 | 0.71 | TSHR (0.52) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL27997819 | 0.71 | JAK2 (0.60) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL28115351 | 0.70 | JAK2 (0.60) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL13708850 | 0.70 | GSK3B (0.54) | HPGD | |
| SCHEMBL3985035 | 0.70 | GSK3B (0.54) | JAK2JAK3BTKHPGD | |
| SCHEMBL11375916 | 0.70 | KDM4E (0.61) | — | |
| SCHEMBL11379798 | 0.70 | KDM4E (0.60) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-12-31 | — | — | US | disclosed |
| CN-101495186-A | Inhibitors of undecaprenyl pyrophosphate synthase | NOVARTIS AG (CH) | 2009-07-29 | — | — | CN | disclosed |
| EP-2059305-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | Novartis Ag (CH) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008014307-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | JAK2 4808/4885JAK1 4836/4885TYK2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.